EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges

Hiroshi Yoshida iD, Daiki Higuchi, Waku Takigawa, Nao Kikkawa, Taro Yamanaka iD, Ayaka Nagao, Mayumi Kobayashi-Kato iD, Masaya Uno iD, Mitsuya Ishikawa iD, Kouya Shiraishi iD

Journal of Personalized Medicine · 31.01.2026 · 16 (2) · 72

DOI: 10.3390/jpm16020072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 31.01.2026. Verfasst von Hiroshi Yoshida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocervical adenocarcinoma is now classified within an etiologic framework based on the presence or absence of high-risk human papillomavirus (HPV) infection. Gastric-type endocervical adenocarcinoma (GAS) is the prototypical HPV-independent subtype, accounting for up to 25% of endocervical adenocarcinomas and showing a particularly high frequency in East Asia. GAS is typically diagnosed at a more advanced stage than usual-type HPV-associated endocervical adenocarcinoma (UEA); exhibits deep stromal and parametrial invasion, lymphovascular space invasion, and a strong propensity for ovarian and peritoneal metastasis; and is associated with markedly worse survival, even in stage I disease. Radiological evaluation is challenging because of diffuse infiltrative growth, prominent mucin production, and frequent underestimation of extra-cervical spread. Histologically, GAS shows gastric-type (pyloric) differentiation, ranging from minimal deviation adenocarcinoma to poorly differentiated forms, and often overlaps with precursor lesions such as atypical lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma in situ. Immunophenotypically, GAS is typically p16-negative, ER/PR-negative, and frequently exhibits mutant-type p53 and expression of gastric markers including MUC6, HIK1083, and claudin 18.2. Recent next-generation sequencing and multi-omics studies have revealed recurrent alterations in TP53, CDKN2A, STK11, KRAS, ARID1A, KMT2D, and homologous recombination-related genes, together with the activation of PI3K/AKT, WNT/β-catenin, TGF-β, and EMT pathways and characteristic metabolic reprogramming. GAS is highly resistant to conventional chemotherapy and radiotherapy, and its current management follows guidelines for squamous and usual-type adenocarcinoma. Emerging data support precision-medicine approaches targeting HER2/HER3, PD-1/PD-L1, and claudin 18.2, and suggest a role for PARP inhibition and other genotype-directed therapies in selected subsets. Given its aggressive biology and rising relative incidence in the HPV-vaccination era, GAS represents a critical unmet need in gynecologic oncology. Future progress hinges on developing reliable diagnostic biomarkers, refining imaging protocols, and validating targeted therapies through international clinical trials.

Schlagwörter

Stichwörter der Autor:innen

cervical cancerclinicopathologic featuresgastric-type adenocarcinomagenetic alterationshistologyimmunohistochemistrytherapeutic targets

Autor:innen und Institutionen

  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Division of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
  • Department of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Department of Radiation Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.

ORCID-Profile: Hiroshi Yoshida, Taro Yamanaka, Mayumi Kobayashi-Kato, Masaya Uno, Mitsuya Ishikawa, Kouya Shiraishi

Zitieren

APA

Yoshida, H., Higuchi, D., Takigawa, W., Kikkawa, N., Yamanaka, T., Nagao, A., Kobayashi-Kato, M., Uno, M., Ishikawa, M., & Shiraishi, K. (2026). Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges. Journal of Personalized Medicine, 16(2), 72. https://doi.org/10.3390/jpm16020072

Vancouver

Yoshida H, Higuchi D, Takigawa W, Kikkawa N, Yamanaka T, Nagao A, et al. Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges. Journal of Personalized Medicine. 2026;16(2):72. doi:10.3390/jpm16020072

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Hiroshi and Higuchi, Daiki and Takigawa, Waku and Kikkawa, Nao and Yamanaka, Taro and Nagao, Ayaka and Kobayashi-Kato, Mayumi and Uno, Masaya and Ishikawa, Mitsuya and Shiraishi, Kouya},
  title = {Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges},
  journal = {Journal of Personalized Medicine},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {72},
  doi = {10.3390/jpm16020072}
}
Kostenlos starten →